2024 Southeastern Chemical Biology and Drug Discovery Symposium (SCBDDS)

Athens, GA – May 14, 2024

Registration Deadline – April 30, 2024.

The 2024 Southeastern Chemical Biology and Drug Discovery Symposium (SCBDDS) will take place on Tuesday, May 14, 2024, at the University of Georgia in Athens, Georgia. The SCBDDS provides a premier forum on the research frontiers of chemical biology, drug discovery and development, and molecular medicine. The attendees will be academic and industrial scientists throughout the U.S., especially in the southeastern region of the nation. The conference will feature cutting-edge research talks by a diverse range of faculty, post-doctoral scholars, and graduate students, selected from submitted abstracts. The symposium will include a poster session to extend discussions and collaborative interactions among scientists from all career stages. The keynote presentation will conclude the event.

 

We look forward to welcoming you on the beautiful campus of UGA.

 

Organizing Committee

Dennis Kyle

Y. George Zheng

Eileen Kennedy

Campbell Mcinnes

Adegboyega K Oyelere

David Crich

Symposium Organizers

Dennis Kyle
University of Georgia

Y. George Zheng
University of Georgia

Eileen Kennedy
University of Georgia

Campbell Mcinnes
University of South Carolina

Adegboyega K Oyelere
Georgia Institute of Technology

David Crich
University of Georgia

Keynote Address

Keynote Speaker: Nathaneal S. Gray, Ph.D.

Dr. Nathanael Gray is the Nancy-Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and the Dana Farber Cancer Institute.  Nathanael leads the Dana Farber Program in Chemical Biology and manages a research laboratory.

Nathanael has pioneered pharmacological approaches to inhibit protein kinases that become dysregulated in cancer and other diseases. His development of innovative strategies for kinase inhibition has enabled discovery of first‐in‐class inhibitors that have become widely used as tools to elucidate kinase function in biological systems and resulted in the development of clinical candidates and approved drugs. Nathanael also pioneered the development of covalent compounds that target unique cysteine residues to achieve selectivity across the approximately 520 human kinases. He developed the first ATP‐competitive inhibitors of mTOR that were used to discover that mTOR regulates protein translation and cell growth more profoundly than previously anticipated. Following this, Dr. Gray developed the concept of ‘mutant‐selective’ kinase inhibitors which resulted in the development of a new class of EGFR inhibitors currently approved for the treatment of lung cancer. Nathanael has contributed to the field of small molecule induced protein degradation and has developed new strategies and approaches for efficiently discovering new degrader molecules.

These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011, the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015.

 

Complete-Materials1
Driving Directions
2018 Coming Soon
2018 Coming Soon
2018 Coming Soon
lodging
travel
activities

Thank you to our SCBDDS 2024 sponsors!

image001
Office of research
New England Biolabs logo. (PRNewsFoto/NEW ENGLAND BIOLABS, INC.)
Molecules-New Logo
college of Pharm